

# How gender influence the health state? A cross sectional study in an endocrine setting

**Marta Bianchini**

Istituto Regina Elena

**Giulia Puliani**

Universita degli Studi di Roma La Sapienza Dipartimento di Medicina Sperimentale

**Alfonsina Chiefari**

Istituto Regina Elena

**Rosa Lauretta**

Istituto Regina Elena

**Marilda Mormando**

Istituto Regina Elena

**Agnese Barnabei**

Istituto Regina Elena

**Irene Terrenato**

Istituto Regina Elena

**Marialuisa Appetecchia** (✉ [marialuisa.appetecchia@ifo.gov.it](mailto:marialuisa.appetecchia@ifo.gov.it))

Istituto Regina Elena IRCCS <https://orcid.org/0000-0002-2124-1335>

---

## Research article

**Keywords:** gender medicine, lifestyle, endocrine disease, oncological comorbidities, determinants of health.

**Posted Date:** November 10th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-103184/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 **Title page**

2 **How gender influence the health state? A cross sectional study in an endocrine setting**

3 Marta Bianchini<sup>1</sup>, Giulia Puliani<sup>1,2</sup>, Alfonsina Chiefari<sup>1</sup>, Rosa Lauretta<sup>1</sup>, Marilda Mormando<sup>1</sup>,  
4 Agnese Barnabei<sup>1</sup>, Irene Terrenato<sup>3</sup> and Marialuisa Appetecchia<sup>1\*</sup>

5 <sup>1</sup> Oncological Endocrinology Unit, IRCCS Regina Elena National Cancer Institute, Via Elio  
6 Chianesi 53, 00144, Rome, Italy;

7 <sup>2</sup> Department of Experimental Medicine, Sapienza University of Rome; Viale Regina Elena 324,  
8 00161, Rome, Italy;

9 <sup>3</sup> Biostatistics and Bioinformatic Unit- Scientific Direction, IRCCS Regina Elena National  
10 Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.

11

12 \*Corresponding Author: Marialuisa Appetecchia, marialuisa.appetecchia@ifg.gov.it; Via Elio  
13 Chianesi 53, 00144, Rome, Italy

## 14 **Abstract**

15 **Background:** Gender medicine focuses on how gender differences affect health status and  
16 diseases development and how they influence health services access and attitude to screening  
17 programmes. Endocrine diseases are influenced by many gender-related issues, some of which  
18 have not been sufficiently investigated. The aim of this study was to evaluate gender difference in  
19 determinants of health (as lifestyle, level of education, area of origin, distance from hospital) and  
20 how these elements could influence diseases prevalence in an endocrine outpatients setting, with a  
21 special focus on oncological disease.

22 **Methods:** We performed a cross-sectional study enrolling patients referring for the first time to our  
23 Oncological Endocrinology Unit, between January 2019 to December 2019.

24 **Results:** We enrolled 1107 consecutive patients. Mean age was  $56.8 \pm 15.0$  years (77% females).  
25 The main reasons for referral were thyroid and bone diseases. We found a gender difference in  
26 some disease prevalences: malignant endocrine diseases and iatrogenic thyroid diseases were more  
27 frequent in males, while other thyroid disorders, adrenal and metabolic diseases and cancer  
28 treatment induced bone loss were higher in females. The frequency of oncological comorbidities  
29 was higher in females. No difference was found in the propensity to travel long distances to reach  
30 the hospital. In our population, women had a higher socio-cultural level and followed healthier  
31 lifestyle. In fact, alcohol and tobacco consumption was lower in females and women had lower  
32 BMI. The percentage of smokers or ex-smokers was higher in patients with any malignancy  
33 compared to patients with benign endocrine diseases.

34 **Conclusions:** the study showed the importance of considering gender as a determinant of health,  
35 able to influence also lifestyle and habits, and as an element to keep in consideration to promote a  
36 healthier lifestyle and a targeted endocrine screening especially in oncological setting.

37 **Keywords:** gender medicine; lifestyle; endocrine disease; oncological comorbidities;  
38 determinants of health.

## 39 **Background**

40 Gender medicine deals with biological, psychological and socio-cultural differences between  
41 men and women, which can affect health status and disease development(1). The term "gender"  
42 goes beyond the simple biological differences between male and female, classically defined as  
43 "sex", taking into account also environmental, social, cultural and relational factors(2). Gender  
44 medicine is therefore a complex study of how these gender differences affect the state of health, the  
45 onset and progression of diseases, the access to health services, the attitude towards prevention  
46 interventions and to therapeutic strategies(3). In fact, men and women, despite being susceptible to  
47 almost the same pathologies, could present different symptoms, disease progression and response  
48 to treatments. In addition, women have a higher propensity to consult health care providers,  
49 generally they take more medication and usually manage family health problems(4).

50 In 2019, Italian Ministry of Health arranged a plan for the application and the diffusion of gender  
51 medicine in the country, testifying its importance in the wider field of precision medicine(5).

52 Gender medicine therefore aims to achieve a "health" condition by paying attention not only to the  
53 disease itself, but also to the "determinants of health" starting from lifestyles such as alcohol,  
54 smoking, physical activity, nutrition and body weight(6). These, in fact, contribute to determining  
55 the health of women and men and have an impact on the incidence of many chronic diseases, such  
56 as cardiovascular and respiratory diseases, diabetes mellitus, and cancer diseases. Exposure to the  
57 aforementioned risk factors depends on individual choices, but it is strongly influenced by the  
58 socio-cultural and environmental context and therefore by gender(7).

59 In modern society, gender medicine appears essential to achieve the best diagnostic and  
60 therapeutic work-up for both men and women and to optimize health services planning(8).

61 Endocrinology is one of the medical disciplines most influenced by issues related to gender, as the  
62 most widespread endocrine diseases (e.g. thyroid diseases, osteoporosis and diabetes mellitus)  
63 have marked gender differences in term of prevalence. This is certainly due to hormonal  
64 differences between males and females, while the impact of gender-related determinants of health  
65 have not yet been sufficiently investigated(9).

66 The aims of our study were:

67 - to evaluate the gender difference in determinants of health as lifestyle, level of education, area of  
68 origin;

69 - to evaluate how and if these determinants could influence the prevalence of endocrine diseases  
70 and oncologic disease;

71 - to assess gender difference in availability to travel long distances in order to gain access to  
72 health services.

### 73 **Methods**

74 This is a cross-sectional study, conducted in our Oncological Endocrinology Unit at Regina  
75 Elena National Cancer Institute of Rome, between January 2019 to December 2019.

76 All patients (age > 18 years) referring to our endocrine center, for the first evaluation in the study  
77 frame-time, were considered potentially eligible. Patients could gain access to our center through  
78 national health system booking service or through selected waiting lists accessible by our  
79 hospital's oncologists.

80 The following parameters were assessed during first visit: sex, age, residence address to calculate  
81 distance from the hospital, ethnicity and nationality, level of education (grade 8 or less: elementary  
82 school and middle school; grade 12 or upper education: high school, degree or upper title), body  
83 mass index (BMI) calculated as the weight (kilograms) divided by the height (meters squared),  
84 smoking status (3 groups: smokers, non-smokers or ex-smokers), alcohol consumption (classified  
85 as yes in case of at least 0.5 UI alcohol units per day or no), physical activity (no, yes moderate or  
86 yes intense), endocrine and oncological diseases (for example: brain, breast, prostate, lung,  
87 gastrointestinal cancers, hemato-lymphoid neoplasms).

88 Endocrine diseases were grouped as follows: pituitary diseases, andrological diseases,  
89 neuroendocrine neoplasms, thyroid cancers, benign thyroid diseases (including thyroid nodules,  
90 thyroiditis, primary hyperthyroidism and hypothyroidism, iatrogenic thyroid disorders induced by  
91 amiodarone, tyrosine kinase inhibitors-TKI, immune checkpoint inhibitors, neck radiotherapy),  
92 bone diseases (including cancer treatment induced bone loss-CTIBL, post-menopausal  
93 osteoporosis and osteopenia, hyperparathyroidism and hypercalcemia), adrenal diseases (including  
94 adrenal hyperplasia, functioning and non-functioning adrenal adenomas and incidentalomas),  
95 diabetes mellitus and metabolic diseases (including diabetes mellitus type 2, obesity, insulin  
96 resistance). Each patient's data were collected using a standardized data collection form.

97 The study was done under the approval of the local ethic committee of Regina Elena National  
98 Cancer Institute and all patients gave written informed consent to participate.

99 *2.1. Statistical analysis*

100 Variables of interest were expressed as frequencies and percentage values while continuous  
 101 variables were expressed as mean  $\pm$  standard deviation. Patients were divided in subgroups  
 102 according to gender and age. Associations among variables were tested with non-parametric  
 103 Chi-square test. Statistically significance was defined at  $p < 0.05$ . All statistical analyses were  
 104 performed using Statistical Packages for Social Sciences (SPSS version 21.0).

## 105 **Results**

### 106 *3.1. Patients' characteristics*

107 In the study timeframe (one year), a total of 1180 patients referred to our endocrine center for  
 108 first examination. 73 patients were excluded from the study due to missing data or refusal to  
 109 participate, so a total of 1107 patients were enrolled in the study: 854 patients were females (77%)  
 110 and 253 were males (23%). Total mean age was  $56.8 \pm 15.0$  years, with a statistically significant  
 111 difference between gender (male:  $60 \pm 16.6$  years, female  $56 \pm 14.3$  years,  $p < 0.001$ ). No gender  
 112 difference was found in ethnicity of patients. A higher proportion of female patients had a  
 113 nationality other than Italian ( $p = 0.008$ , 29 patients from European Union, 5 from South America,  
 114 16 from Asia, 2 from Africa).

115 **Table 1. Patients' characteristics.**

	<b>Male</b> N= 253 (23%)	<b>Female</b> N=854 (77%)	<b>p value</b>
<b>Age</b>	$60 \pm 16.6$	$56 \pm 14.3$	$< 0.001^*$
Age $\leq$ 45 years	50 (19.9%)	202 (23.7%)	0.209 <sup>#</sup>
Age $>$ 45 years	201 (80.1)	650 (73.6%)	
<b>Ethnicity</b>			
Caucasian n (%)	250 (98.8%)	839 (98.6%)	1.0 <sup>#</sup>
Others n (%)	3 (1.2%)	12 (1.4%)	

<b>Nationality</b>			
Italian	249 (98.4%)	806 (94.4%)	0.008*#
Others	4 (1.6%)	48 (5.6%)	
<b>Level of education</b>			
Grade 8 or lower	86 (38.2%)	239 (30.3%)	0.024*#
Grade 12 or upper education	139 (61.8%)	551 (69.7%)	
<b>Distance from the hospital</b>			
≤ 10 Km	51 (20.2%)	189 (22.1%)	0.229#
10-20 Km	79 (31.2%)	223 (26.1%)	
20-30 Km	39 (15.4%)	169 (19.8%)	
>30 Km	84 (33.2%)	272 (31.9%)	
<b>Determinants of health</b>			
BMI	27.8 ± 5.0	26.1 ± 5.5	<0.001*
<i>Smoking status</i>			
Smokers or ex-smokers	150 (59.8%)	356 (42.0%)	<0.001*#
No smokers	101 (40.2%)	492 (58.0%)	
<i>Alcohol Consumption</i>			
No	125 (50.8%)	559 (67.0%)	<0.001*#
Yes	121 (49.2%)	275 (33.0%)	
<i>Physical activity</i>			
No	139 (65.0%)	468 (63.8%)	0.854#
Yes, moderate	69 (32.2%)	240 (32.7%)	
Yes, intense	6 (2.8%)	26 (3.5%)	

116 Legend and abbreviations: \*=statistically significant differences between groups; #= chi-square  
117 test. Values are expressed as mean± standard deviation if not otherwise stated are cited.

### 118 3.2. Reason for referral

119 Patients of both genders referred to our center mainly for thyroid diseases. The secondary most  
120 frequent reason was bone disease. Among patients referring for benign endocrine diseases, there  
121 was a high prevalence of oncological comorbidity. In fact, at list one malignancy was present in  
122 56.1% of patients with benign endocrine disease compared to only 14.5% of patients with  
123 endocrine malignancies, with a statistically significant difference (p<0.001). Considering gender,

124 malignant endocrine diseases were more frequent in males than in females (11.5% vs 5.3%,  
 125  $p < 0.001$ ). All reasons for referral are summarized in Table 2.

126 **Table 2. Reasons for referral.**

	<b>Male</b> N= 253 (23%)	<b>Female</b> N=854 (77%)
Benign thyroid diseases	147 (58.1%)	476 (55.7%)
Thyroid cancers	19 (7.5%)	39 (4.6%)
Bone diseases	22 (8.7%)	247 (28.9%)
Adrenal diseases	21 (8.3%)	37 (4.3%)
Pituitary diseases	9 (3.6%)	14 (1.6%)
Neuroendocrine neoplasms	10 (4.0%)	6 (0.7%)
Diabetes mellitus and metabolic diseases	9 (3.6%)	18 (2.1%)
Andrological diseases	9 (3.6%)	NA
Others	7 (2.8%)	17 (2.0%)

127 Values are expressed as number of patients (percentage). NA= not applicable.

128 *3.3. Disease prevalence according to gender*

129 Most patients referred to our Unit for just one endocrine disease (corresponding to the reason  
 130 for referral), while a lower but significant percentage of patients had more than one disease: in  
 131 particular, 227 patients had two endocrine diseases and 23 patients had 3 endocrine  
 132 diseases. Global diseases prevalence is summarized in Table 3. The most frequent group of  
 133 disorders were benign thyroid diseases, without gender difference ( $p = 0.517$ ). In a subgroup  
 134 analysis, percentage of iatrogenic thyroid disorders (induced by amiodarone, TKI, immune  
 135 checkpoint inhibitors, neck radiotherapy) was higher in males (10.6%, vs 1.4% in females,  
 136  $p < 0.001$ ), while no statistically significant difference was found in percentage of patients with  
 137 thyroid nodules according to gender (70% in males, 69.9% in females,  $p = 0.77$ ). Consequently,

138 females had higher prevalence of remaining thyroid diseases (hypothyroidism and  
139 hyperthyroidism, thyroiditis).

140 There was a statistically significant difference in the proportion of females and males affected by  
141 bone diseases (respectively, 36.1% vs 10.7%,  $p < 0.001$ ); in this group most patients had CTIBL and  
142 only a minority of patients had other bone diseases not related to cancer, such as post-menopausal  
143 osteoporosis or disorders of calcium metabolism in both gender. Considering CTIBL prevalence,  
144 there was a statistically significant difference between males and females (27.3% vs 7.1%,  
145  $p < 0.001$ ).

146 In our population, there was no gender difference in the prevalence of pituitary diseases ( $p = 0.288$ ),  
147 while adrenal and metabolic diseases were higher in females (respectively  $p = 0.002$  and  $p = 0.024$ ).  
148 Considering malignancies, a higher proportion of males referred for neuroendocrine neoplasms  
149 (4.0% vs 0.7%,  $p < 0.001$ ) and thyroid cancers (7.9% vs 4.7%,  $p = 0.047$ ), while females had a higher  
150 prevalence of oncological comorbidities than males ( $p = 0.005$ ). In the subgroup of patients affected  
151 by oncological comorbidities, a higher percentage of women had CTIBL than men (45.0% vs  
152 16.1%,  $p < 0.001$ ).

153 **Table 3. Diseases prevalence**

	<b>Male N= 253 (23%)</b>	<b>Female N=854 (77%)</b>
Benign thyroid diseases	160 (63.2%)	559 (65.5%)
Thyroid cancers	20 (7.9%)	40 (4.7%)
Bone diseases	27 (10.7%)	308 (36.1%)
Adrenal diseases	23 (9.1%)	35 (4.1%)
Pituitary diseases	9 (3.6%)	20 (2.3%)
Neuroendocrine neoplasms	10 (4.0%)	6 (0.7%)
Diabetes mellitus and metabolic diseases	27 (10.7%)	55 (6.4%)
Andrological diseases	9 (3.6%)	NA

Others	7 (2.8%)	19 (2.2%)
Oncological comorbidities	115 (45.5%)	474 (55.5%)

154 This Table takes in consideration all patients diseases. Values are expressed as number of patients  
155 (percentage). NA= not applicable.

### 156 3.4. Gender-related determinants of health

157 No difference was found in physical activities between males and females ( $p=0.854$ ), and this  
158 data was confirmed also dividing patients in two age groups (under and over 45 years).

159 Men had a statistically significant higher BMI compared to women ( $27.8 \pm 5.0$  vs  $26.1 \pm 5.5$  kg/m<sup>2</sup>,  
160  $p<0.001$ ). A higher proportion of males was smokers or ex-smokers compared to females  
161 ( $p<0.001$ ); accordingly, 58% of women had never smoked in their life compared to only 42% of  
162 males. Dividing the study population in two groups according to age, in younger people there was  
163 no statistically significant difference in smoking habits regarding to sex, while in people older than  
164 45 years there was a statistically significant gender difference in the proportion of smokers  
165 ( $p<0.001$ ). Also alcohol consumption was higher in males than in females (49.2 vs 33.0%,  
166  $p<0.001$ ). As smoking habits, there was a difference in alcohol habits only in older  
167 patients( $p<0.001$ ).

168 No difference was found in smoking status, physical activity and alcohol consumption regarding  
169 nationality (comparing Italian and foreign patients), neither between patients referring for benign  
170 and malignant endocrine diseases. However, gathering together people with any malignancies,  
171 both endocrine or non-endocrine, the percentage of smokers or ex-smokers was higher compared  
172 to the group without malignancies ( $p=0.041$ ), while no difference in proportion was found  
173 regarding physical activity and alcohol consumption.

174 In our study population, women had a higher level of education compared to men ( $p=0.024$ ), as  
175 well as not Italian people had more frequently a degree or upper title compared to Italian patients  
176 (39.1% vs 23%,  $p= 0.02$ ).

177 Only 22% of patients lived nearby the hospital (<10 km). The prevalence of malignant endocrine  
178 disease was 7.7% in the group of patients who lived far from the hospital (>10 km) versus 3.8% in  
179 patients who lived closer ( $p= 0.031$ ). No significant difference was found in the distance from the  
180 hospital according to gender, nationality or non-endocrine oncological comorbidities.  
181 Gender-related determinants of health are summarized in Table 1.

## 182 **Discussion**

183 Gender medicine has recently received increasing attention(10). In this perspective, we  
184 decided to design this cross-sectional study in order to provide an overview of our patients,  
185 focusing on the role of gender on endocrine diseases, risks factors and other important aspects  
186 related to health care, always in a gender perspective. Many studies in the literature have focused  
187 on the impact of gender on lifestyle(11). Men seem more prone to consume alcohol and to develop  
188 alcohol-related diseases compared to women(12). Conversely, women who physiologically  
189 tolerate lower amount of alcohol (due to the sex differences in gastric absorption and metabolism),  
190 usually drink less alcohol also for cultural reason, as society's disapproval of drinking or increased  
191 risk of physical and sexual assault(12, 13).

192 In our population, we confirmed a gender difference in alcohol consumption, which was lower in  
193 females. Interestingly, this difference was not statistically significant in younger people, testifying  
194 as younger women have a more similar lifestyle to males, perhaps due to female emancipation,

195 while in older people traditional gender differences are yet more preserved. Likewise, a higher  
196 proportion of men was smokers than women. In Italy, data from two recent tobacco use surveys  
197 show a smoking prevalence of 26% in men compared to 17.2% in women. This gender difference is  
198 reduced in young adults: in Italian adolescents (15-24 years), 21.9% of boys are smokers against  
199 18.2% of girls(14). Therefore, these studies underline that the use of tobacco in young women is a  
200 behavior to be monitored carefully. The relevant gender difference in tobacco use has been  
201 confirmed by Italian Ministry of Health, in a Tobacco Prevention and Control Report based on  
202 ISTAT data: the estimated smoking prevalence is 19.8% (24.8% males and 15.1% females)(15).  
203 These data are consistent with our results: in the whole study population, men were more  
204 frequently smokers or ex-smokers compared to women but, considering only patients aged 45 or  
205 less (born after Italian women emancipation) this difference has not been confirmed, testifying to a  
206 change in lifestyle in new generations. Several factors should be considered in the relationship  
207 between smoking and female gender. Low sociocultural and educational levels and living in  
208 developing countries are known to be risk factors for the onset of tobacco consumption(16, 17). In  
209 the last years the proportion of women who become smoker has increased, mainly due to women's  
210 earning power and targeted marketing by tobacco companies(18).

211 Scientific research has also shown differences in food intake and the practice of physical activity in  
212 both sexes(19, 20). For example, in modern Western societies, the male gender seems to prefer red  
213 meat, high protein foods and sugar-sweetened beverages, while healthier foods such as vegetables,  
214 fruit, fish and dairy products are mostly eaten by women(20-22). These differences may depend on  
215 a different awareness of the relationship between food behavior and health and on a different

216 attention to weight control or good physical shape, in line with modern society stereotypes(23).  
217 This attitude is reflected in the nutritional pattern and body mass index. Unfortunately, we did not  
218 collect information on dietary habits of our patients, but males had a higher BMI compared to  
219 women, testifying to probably less healthy dietary habits. In our population, there were no  
220 differences in physical activity level between males and females, unlike other studies published in  
221 literature which have shown, especially in younger people, a greater propensity to physical  
222 activities in males than in females(24, 25).

223 Taking all these aspects together, in our study population, women seem to follow a healthier  
224 lifestyle. This data could depend on the influence of multiple factors. First, women pay greater  
225 attention to their health condition compared to men(4); secondary, it is the conditioning of society  
226 that leads women to maintain a good body shape in order to achieve beauty stereotypes; finally, the  
227 level of education of patients. Indeed, in our population, women had a higher level of education  
228 compared to men and this could have affected the lifestyle of our patients. It is demonstrated that  
229 better educated people follow a healthier lifestyle, probably due to the increased awareness of the  
230 correlation between lifestyle and health(26).

231 National habits also seem to influence the state of health; in fact, in our study, foreign people  
232 (mainly women from European Union States) did not follow a healthier lifestyle than Italian  
233 patients, despite their higher education level.

234 During a year, the percentage of women referring for a first endocrine visit was significantly higher  
235 than men. This fact could be explained by the more common prevalence of endocrine diseases in

236 females(27), but also by the higher attention paid to personal health status typical of women and  
237 their higher propensity to refer to health care centers(1).

238 One of the aims of our study was to ascertain if women were more willing than men to travel long  
239 distances for obtaining medical care. The willingness to move from own home area to reach  
240 tertiary center health care was the same in both sexes and did not change according to nationality;  
241 in fact, most patients decided to go to a qualified cancer endocrinology center, even if it was not  
242 close to their residences. This was particularly true for patients with endocrine tumors who showed  
243 a higher propensity to travel long distances. It is important to consider that a relevant part of the  
244 first access to our center was allowed regardless of the reported disease, considering that the  
245 booking service of the Italian public health system does not indicate to the patients the most  
246 suitable hospital. According to this, the reason for referral to our center was only partially biased  
247 by the type of center (Oncological Endocrine Unit).

248 The most common reason for referral to our center was an endocrine malignancy or a benign  
249 endocrine disease associated to other oncological comorbidities, probably because our center is a  
250 national reference hospital for neoplastic diseases. In our population, women had a higher  
251 prevalence of oncological comorbidities: a high percentage of these patients referred to the  
252 Endocrine Unit for prevention and treatment of cancer induced bone loss, mainly due to the intake  
253 of aromatase inhibitors or gonadotropin-releasing hormone analogs for breast cancers.

254 Benign thyroid diseases were the most common endocrine disorders in both sexes; this finding  
255 could be explained by the high prevalence of thyroid nodules. The increased prevalence in our  
256 population could be caused by the fact that oncological patients undergo multiple and deepened

257 whole body radiological examinations (such as computed tomography and magnetic resonance  
258 imaging) and functional procedures (such as positron emission tomography), therefore thyroid  
259 nodules can be an accidental finding(28), and patients have been referred to our Unit for  
260 subsequent tests, such as the fine needle aspiration diagnostic biopsy of the thyroid nodule.

261 Furthermore, there was no gender difference in the prevalence of benign thyroid disease, although  
262 some disorders, such as Hashimoto's thyroiditis or thyroid nodules, are known to be more frequent  
263 in females(27). However, this finding could be explained considering that in our population this  
264 group of diseases also contains drug related thyroid dysfunction (e.g. due to TKI or amiodarone  
265 intake) or subclinical thyroid disease due to age or chronic diseases, which usually do not showed  
266 significant gender differences(29, 30).

267 Probably, the high incidence of adrenal incidentalomas could be explained by the high number of  
268 radiological and functional tests performed in our Hospital for the cancer diagnosis and for  
269 patients' follow-up.

270 In our study, thyroid malignancies were more frequent in males than females. The risk of  
271 malignancy of the thyroid nodules is known to be greater in males(31, 32), and that male gender is  
272 an independent prognostic factors in papillary thyroid carcinoma, which influences staging and  
273 risk of recurrence(33, 34). These factors together could explain the propensity to refer to a national  
274 cancer center in male patients.

275 We therefore sought to evaluate the impact of common gender-influenced risk factors in the higher  
276 prevalence of endocrine malignancies found in males.

277 In patients with at least one tumor (endocrine or non-endocrine), the percentage of smokers and  
278 ex-smokers was higher compared to patients without neoplasms.

279 This finding has not been confirmed considering only patients with endocrine malignancies,  
280 probably due to the low number of patients affected and also considering that for some of these  
281 malignancies (for example thyroid cancer) other risk factors are of considerable importance, such  
282 as family history or previous radiation exposure(32, 35).

283 In a gender medicine perspective, it should be also interesting to evaluate possible differences  
284 between men and women in terms of inclination in carrying out periodic follow-up visits and  
285 adherence to the treatment proposed by physician, with possible impact on progression and  
286 outcomes of the endocrine disorders. Unfortunately, we do not have data on these aspects in our  
287 population, as only one visit per patient has been analysed, but this topic is of a great interest for  
288 further studies.

## 289 **Conclusions**

290 Biological and sociocultural aspects are known to influence lifestyle, patient health, disease  
291 development and treatment adherence. The study highlights and confirms the importance of  
292 considering gender and gender-related health determinants as key factors for health, even in  
293 patients affected by endocrine diseases, in which this approach has not been widely used.

294 Our study demonstrated that smoking and alcohol consumption are more common in males and  
295 younger women. Therefore, in the approach to the patient, doctors should pay special attention to  
296 female and male lifestyle, in order to discourage voluptuous habits and to encourage physical  
297 activity and healthy eating habits. This is particularly important mainly in subjects who, nowadays,

298 seem to be less careful to these aspects, as men, younger women or patients with lower  
299 socio-cultural level.

300 Our study confirmed, as already known in the literature, that women were more affected by  
301 endocrine disorders but, in our cohort, the proportion of endocrine malignancies was higher in  
302 men. Therefore, from a precision medicine perspective, all efforts must be made to raise  
303 awareness, in oncological patients and health care providers, on the risk of endocrine diseases  
304 development in order to promote targeted screening in both genders.

#### 305 **List of abbreviations:**

306 TKI: tyrosine kinase inhibitors; CTIBL: cancer treatment induced bone loss; BMI: body mass  
307 index.

#### 308 **Declarations**

##### 309 **Ethics approval and consent to participate**

310 The study has been approved by the local ethic committee of Regina Elena National Cancer  
311 Institute (reference number: 1370/20). All patients give written informed consent to study  
312 participation.

##### 313 **Availability of data and materials**

314 The datasets generated during the current study are available in the GARR repository,  
315 [<https://www.garr.it/it/>]

##### 316 **Competing interests**

317 The authors declare they have no competing interests.

318 **Funding**

319 Not applicable

320 **Author Contributions**

321 MB: Study conduction, data collecting, initial data analysis, writing – original draft. GP: Data  
322 control, initial data analysis, writing – original draft. AC, RL, MM, AB: Data collecting. IT:  
323 Statistical analysis. M.A.: study conception and design, supervision, writing – review & editing.  
324 All authors have read and agreed to the published version of the manuscript.

325 **References**

- 326 1. McGregor AJ, Templeton K, Kleinman MR, Jenkins MR. Advancing sex and gender  
327 competency in medicine: sex & gender women's health collaborative. *Biol Sex Differ.*  
328 2013;4(1):11.
- 329 2. Ristvedt SL. The evolution of gender. *JAMA Psychiatry.* 2014;71(1):13-4.
- 330 3. Legato M. *Principles of Gender-Specific Medicine.* 2nd Edition. Elsevier. 2011.
- 331 4. Cortese DA. A vision of individualized medicine in the context of global health. *Clin*  
332 *Pharmacol Ther.* 2007;82(5):491-3.
- 333 5. [http://www.salute.gov.it/imgs/C\\_17\\_pubblicazioni\\_2860\\_allegato.pdf](http://www.salute.gov.it/imgs/C_17_pubblicazioni_2860_allegato.pdf).
- 334 6. Vlassoff C. Gender differences in determinants and consequences of health and illness. *J*  
335 *Health Popul Nutr.* 2007;25(1):47-61.
- 336 7. Legato MJ, Johnson PA, Manson JE. Consideration of Sex Differences in Medicine to  
337 Improve Health Care and Patient Outcomes. *JAMA.* 2016;316(18):1865-6.
- 338 8. Peres A. Gender-specific medicine in clinical research and health policy implications. *Italian*  
339 *Journal of Gender-Specific Medicine.* 2018;4(2):45-6.
- 340 9. Lauretta R, Sansone M, Sansone A, Romanelli F, Appetecchia M. Gender in Endocrine  
341 Diseases: Role of Sex Gonadal Hormones. *Int J Endocrinol.* 2018;2018:4847376.
- 342 10. Baggio G. [Gender medicine: a interdisciplinary approach to medicine.]. *G Ital Med Lav*  
343 *Ergon.* 2017;39(3):196-8.
- 344 11. Vari R, Scazzocchio B, D'Amore A, Giovannini C, Gessani S, Masella R. Gender-related  
345 differences in lifestyle may affect health status. *Ann Ist Super Sanita.* 2016;52(2):158-66.
- 346 12. Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences:  
347 Contemporary knowledge and future research considerations. *Drug Alcohol Depend.*  
348 2015;156:1-13.
- 349 13. Agabio R, Pisanu C, Gessa GL, Franconi F. Sex Differences in Alcohol Use Disorder. *Curr*  
350 *Med Chem.* 2017;24(24):2661-70.

- 351 14. Lugo A, Zuccaro P, Pacifici R, Gorini G, Colombo P, La Vecchia C, et al. Smoking in Italy in  
352 2015-2016: prevalence, trends, roll-your-own cigarettes, and attitudes towards incoming  
353 regulations. *Tumori*. 2017;103(4):353-9.
- 354 15. <http://www.istat.it/it/files/2016/12/Asi-2016.pdf>.
- 355 16. Giskes K, Kunst AE, Benach J, Borrell C, Costa G, Dahl E, et al. Trends in smoking behaviour  
356 between 1985 and 2000 in nine European countries by education. *J Epidemiol Community Health*.  
357 2005;59(5):395-401.
- 358 17. Harrell JS, Bangdiwala SI, Deng S, Webb JP, Bradley C. Smoking initiation in youth: the roles  
359 of gender, race, socioeconomic, and developmental status. *J Adolesc Health*. 1998;23(5):271-9.
- 360 18. Shafey O, Fernandez E, Thun M, Schiaffino A, Dolwick S, Cokkinides V. Cigarette  
361 advertising and female smoking prevalence in Spain, 1982-1997: case studies in International  
362 Tobacco Surveillance. *Cancer*. 2004;100(8):1744-9.
- 363 19. Li KK, Concepcion RY, Lee H, Cardinal BJ, Ebbeck V, Woekel E, et al. An examination of  
364 sex differences in relation to the eating habits and nutrient intakes of university students. *J Nutr*  
365 *Educ Behav*. 2012;44(3):246-50.
- 366 20. Rolls BJ, Fedoroff IC, Guthrie JF. Gender differences in eating behavior and body weight  
367 regulation. *Health Psychol*. 1991;10(2):133-42.
- 368 21. Fagerli RA, Wandel M. Gender differences in opinions and practices with regard to a "healthy  
369 diet". *Appetite*. 1999;32(2):171-90.
- 370 22. Yahia N, Wang D, Rapley M, Dey R. Assessment of weight status, dietary habits and beliefs,  
371 physical activity, and nutritional knowledge among university students. *Perspect Public Health*.  
372 2016;136(4):231-44.
- 373 23. Ferguson C, Winegard B, Winegard B. Who Is the Fairest One of All? How Evolution Guides  
374 Peer and Media Influences on Female Body Dissatisfaction. *Rev Gen Psychol* 2011;15(1):11-28.
- 375 24. Salles-Costa R, Heilborn ML, Werneck GL, Faerstein E, Lopes CS. [Gender and leisure-time  
376 physical activity]. *Cad Saude Publica*. 2003;19 Suppl 2:S325-33.
- 377 25. Solmon MA. Physical education, sports, and gender in schools. *Adv Child Dev Behav*.  
378 2014;47:117-50.
- 379 26. Brobeck E, Bergh H, Odenrants S, Hildingh C. Lifestyle advice and lifestyle change: to what  
380 degree does lifestyle advice of healthcare professionals reach the population, focusing on gender,  
381 age and education? *Scand J Caring Sci*. 2015;29(1):118-25.
- 382 27. Vanderpump MP. The epidemiology of thyroid disease. *Br Med Bull*. 2011;99:39-51.
- 383 28. Russ G, Leboulleux S, Leenhardt L, Hegedus L. Thyroid incidentalomas: epidemiology, risk  
384 stratification with ultrasound and workup. *Eur Thyroid J*. 2014;3(3):154-63.
- 385 29. Maqdasy S, Benichou T, Dallel S, Roche B, Desbiez F, Montanier N, et al. Issues in  
386 amiodarone-induced thyrotoxicosis: Update and review of the literature. *Ann Endocrinol (Paris)*.  
387 2019;80(1):54-60.
- 388 30. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR. Longitudinal  
389 changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars  
390 study. *J Clin Endocrinol Metab*. 2012;97(11):3944-50.
- 391 31. Mettler J, Arnefti S, Schmidt M, Faust M, Engels M, Chiapponi C. Benign Thyroid Diseases:  
392 Are There Gender-Specific Differences for Diagnosis and Treatment of Nontoxic Thyroid

- 393 Nodules? Results from a 4-Year Retrospective Analysis of an Endocrine Tumor Board. *Visc Med.*  
394 2020;36(1):28-33.
- 395 32. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American  
396 Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione  
397 Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management  
398 of Thyroid Nodules--2016 Update. *Endocr Pract.* 2016;22(5):622-39.
- 399 33. Kao YH, Gan HK, Zaheer S, Lam WW, Loke KS, Wong WY, et al. Gender, Race, and Age at  
400 Diagnosis as Risk Factors for Metastasis or Recurrence among 1,657 Thyroid Cancer Patients  
401 Treated with Radioiodine across 40 Years in Singapore. *Oncol Res Treat.* 2015;38(12):679-82.
- 402 34. Ding J, Wu W, Fang J, Zhao J, Jiang L. Male sex is associated with aggressive behaviour and  
403 poor prognosis in Chinese papillary thyroid carcinoma. *Sci Rep.* 2020;10(1):4141.
- 404 35. Su X, Li Z, He C, Chen W, Fu X, Yang A. Radiation exposure, young age, and female gender  
405 are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a  
406 meta-analysis. *Oncotarget.* 2016;7(13):16716-30.  
407